FRANKFURT May 15 German drugmaker Bayer
and its development partner Algeta won
approval from U.S. regulators for a prostate cancer drug that
could eventually generate more than 1 billion euros ($1.31
billion) in annual sales.
The U.S. Food and Drug Administration, which has reviewed
Xofigo under its priority programme, said on Wednesday the
injection is cleared for treatment of bone metastases in men
whose cancer has spread after receiving medical or surgical
therapy to lower testosterone.
Bayer licensed Xofigo, also called radium-223 dichloride,
from Norway's Algeta in 2009 and the two companies will
co-promote the injection in the U.S.
Bayer has also requested approval for the drug in Europe,
where it would market the drug alone.
The drug, which according to Bayer could become a
"blockbuster" product with annual sales of least 1 billion
euros, has some properties of calcium. That makes it cling to
cancerous bone cells and then destroy them via alpha rays, which
is more targeted than the shotgun approach of conventional